相关实验视频

Updated: Apr 15, 2026

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA

Published on: August 21, 2016

血代谢物在炎症蛋白-淋巴瘤因果关系中的介导作用:孟德尔随机化研究

Yueru Ji¹, Xiaotong Gao¹, Li Liu¹

¹Department of Hematology, Tangdu Hospital, Air Force Medical University, Xi'an City, People's Republic of China.

Current medicinal chemistry

|October 6, 2025

概括

循环炎症蛋白 (CIPs) 因果影响扩散大B细胞淋巴瘤 (DLBCL) 风险. 代谢途径部分调解这些效应,为DLBCL提供潜在的治疗点.

科学领域:

遗传学是一个遗传学.
免疫学免疫学免疫学
在瘤学瘤学.

背景情况:

扩散性大B细胞淋巴瘤 (DLBCL) 发病因缺乏与循环炎性蛋白质 (CIP) 和代谢物明显的因果关系.
观察性研究受到混和反向因果关系的限制.
之前的孟德尔随机化 (MR) 研究缺乏双向设计和多组合集成.

研究的目的:

使用双向MR方法调查CIP,代谢物和DLBCL风险之间的因果关系.
整合多学科数据,以全面了解DLBCL病原性.
确定影响DLBCL的潜在代谢物介导途径.

主要方法:

采用双向的两样 MR 设计与反变量加权 (IVW).
利用来自Olink蛋白质组数据 (14,824名参与者) 的91个CIP的遗传仪器.
从FinnGen获得DLBCL遗传关联 (1,050例;314,193对照),并从GWAS目录获得代谢物数据 (1,091种代谢物).

主要成果:

十个CIP显示对DLBCL风险的因果作用;六个增加风险 (例如IL-10,TSLP) 和四个是保护性的 (例如CD40,CXCL9).
对于七种蛋白质,反向因果关系被排除在外.
调解分析表明,1-甲基胺调解了CD5对DLBCL的保护作用的17.2%.

结论:

CIPs被确定为DLBCL病变的因果因素.
代谢物介导的途径代表了DLBCL中的新型机械联系.
血炎症蛋白和代谢途径是DLBCL干预的潜在治疗点.

关键词:

扩散大的B细胞淋巴瘤.IVW方法 IVW方法循环中的炎症蛋白质.免疫微环境免疫微环境门德尔的随机化是门德尔的随机化血清代谢物的血清代谢物

更多相关视频

Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation

Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation

Published on: September 20, 2017

相关概念视频

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...